ERBB2 and breast carcinoma: Compared with that report, the cytotoxicity of Tmab plus αCD137 mAb-mediated ADCC against the HER2-low-expressing human pancreatic cancer cell line was slightly inferior to that against HER2-high-expressing human breast cancer cell lines because more NK cells were required to achieve the same level of ADCC in the former.